Decoding Glioblastoma Through Liquid Biopsy: Molecular Insights and Clinical Prospects
Cells · 2026
DOI: 10.3390/cells15030309 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2026. Verfasst von Tomasz Wasiak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7/9 St., 90-752 Lodz, Poland. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lodz, LEK-AM Pharmaceutical Company Ltd..
Abstract (Originalsprache)
Liquid biopsy (LB) offers a minimally invasive approach to characterizing and monitoring glioblastoma (GB), a tumor marked by extensive heterogeneity, limited surgical accessibility and rapid molecular evolution. By analyzing circulating tumor-derived components such as circulating tumor DNA (ctDNA), extracellular vesicles (EVs), circulating RNA species and circulating tumor cells (CTC), LB provides dynamic molecular information that cannot be captured by neuroimaging or single-site tissue sampling. Cerebrospinal fluid (CSF) currently yields the highest sensitivity for detecting tumor-specific alterations, while plasma enables repeat monitoring despite lower biomarker abundance. EVs have gained particular prominence due to their ability to preserve DNA, RNA, and protein cargo that reflects key genomic changes, treatment resistance mechanisms, and immune evasion. Although advances are substantial, clinical implementation remains constrained by low analyte concentrations, methodological variability, limited standardization and the high cost of testing, which is rarely reimbursed by insurers. This review summarizes current evidence on circulating biomarkers in GB and highlights research priorities essential for integrating LB into future diagnostic and therapeutic workflows.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7/9 St., 90-752 Lodz, Poland.
- Department of Research and Development, LEK-AM Pharmaceutical Company Ltd., Inwestycyjna 7 St., 95-050 Konstantynow Lodzki, Poland.
ORCID-Profile: Tomasz Wasiak, Kamil Filiks, Adrianna Rutkowska
Förderung
- Medical University of Lodz
- LEK-AM Pharmaceutical Company Ltd.
Zitieren
APA
Wasiak, T., Jaskólska, M., Filiks, K., Bartkowiak, J., & Rutkowska, A. (2026). Decoding Glioblastoma Through Liquid Biopsy: Molecular Insights and Clinical Prospects. Cells. https://doi.org/10.3390/cells15030309
Vancouver
Wasiak T, Jaskólska M, Filiks K, Bartkowiak J, Rutkowska A. Decoding Glioblastoma Through Liquid Biopsy: Molecular Insights and Clinical Prospects. Cells. 2026. doi:10.3390/cells15030309
BibTeX
@article{Wasiak2026,
author = {Wasiak, Tomasz and Jaskólska, Maria and Filiks, Kamil and Bartkowiak, Jakub and Rutkowska, Adrianna},
title = {Decoding Glioblastoma Through Liquid Biopsy: Molecular Insights and Clinical Prospects},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15030309}
}
EUVIMED